Episode Details
Back to Episodes
In the News... New islets study, Tzield for babies, MiniMed Go approved, Civica insulin launched, and more!
Description
It's In the News... the top diabetes stories and headlines happening now! Top stories this week include: new islet encapsulation trial, FDA agrees to review Tzield for babies and approves the MiniMed Go, Civica releases it's version of Lantus, Eversense launches with a pump partner, scholarship for college students with diabetes and more!
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)
All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com
Episode transcript:
Welcome!
This is an In the News episode.. we're doing things a little differently this year, but we are still bringing you the top diabetes stories and headlines happening now.
We are rotating these shorter episodes with our longer, interview episodes.. but all on Tuesdays now. And that's why you'll hear ads on the in the news episodes. My usual disclaimer – we believe in the products advertised here but no one tells me what stories to run or what to say – the commercials are separate from the news. I know most podcasters don't do disclaimers anymore, but I come from traditional broadcasting and it's still important to me.
Okay.. our top story this week:
XX
Positive results for a phase 1 clinical trial of encapsulated islets in people with type 1 from Encellin. This first-in-human trial is assessing (1) safety and adverse events, (2) cell survival within the device, and (3) fibrosis, or scarring, around the implants.
As planned, ENCRT devices were removed from the initial five participants after 4 months of implantation. Analysis of the removed devices show:
minimal to no fibrosis (formation of scar tissue around the device);
robust formation of blood vessels